Clinical Trial Update: A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults [Phase 3]

View source ↗

Summary

This long-term follow-up analysis from two Phase 3 studies evaluates the durability of efficacy, safety, and immunogenicity of GSK's Herpes Zoster Subunit (HZ/s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Zoster, Herpes Zoster Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2024-09-19